Z.I.A.D. Healthcare for the Underserved Inc. is a 501c3 Non Profit organization that came to be in 2002 when four individuals sat down and looked for ways to help provide access to the uninsured. Specifically they looked at those that fall through cracks, some 46,000,000 people in the United States. These are the people that work part time jobs (making them unqualified for governmental assistance), and receive no coverage from their employers, and cannot afford the premiums of health insurance.
Z.I.A.D. derives its name from the names of its founders Ray Zak, Iqbal Nasser MD, Ibraham Ahmed ND, Theodore Densley MD. Z.I.A.D. primarily works with private doctors to find a primary care home for the uninsured on a sliding scale program where they receive reduced office costs based on federal poverty guidelines.
If you are a primary care office and would like to participate in the program please call 313-815-8767.
A plain-language guide to placebo-controlled trials, including randomization, blinding, active comparators, ethics, and what beating placebo really means.
A daily multivitamin can help cover some nutrient shortfalls, but research does not show broad protection against heart disease, cancer, or early death in generally healthy adults.
Waist circumference is a practical marker of central adiposity, but it is not a diagnosis. Learn how to measure it and interpret the result in context.
Obstructive sleep apnea overlaps with obesity, hypertension and impaired glucose regulation, but shared risk factors complicate the relationship. Here is what the evidence says about CPAP, weight reduction and tirzepatide.
Inflammation is a protective immune response, not automatically a disease. This guide explains acute and persistent inflammation, common signs, causes, and the limits of inflammatory blood tests.
Music festivals should get stickers printed from a company that can handle big color, fast-moving event deadlines, outdoor durability, sponsor needs, merch tables, VIP bags,
On August 9, 2022 Ray Zak the president of the board of ZIAD received a prestigious award from the Wayne County Health Authority for the work done by him in leadership of ZIAD Healthcare for the Underserved.
The plaque was awarded and titled “The Best Safety Net Award” with the following inscription:
“On The ninth day of August , 2022, in recognition for extraordinary commitment and service to community health care, we recognize Ray Zak.” The plaque was signed by Gail Warden and Chris Allen of the Wayne County Health Authority. Congratulations to Ray Zak on his devoted leadership of Z.I.A.D.
ZIAD Health Care for the Underserved participated in a health and community fair at Resurrection Lutheran Church Kelly Rd., Detroit, MI.. ZIAD provided the community with information on services that are available for the uninsured, and also provided Free Blood Pressure screening.The event was a cooperative program of three Lutheran churches in the Detroit area. Many residents turned out for the free information, screening, community togetherness, and some free hot dogs. Click here to see pictures from the event.
As always for information on health care call ZIAD at 313-815-8767
A Letter from the HeartDear Friends of ZIAD,
I have been blessed my entire life with the luxury of health insurance. My Father provided for me when I was a child, and I have been fortunate enough in my adult life to provide coverage for myself and my family. Recently, however, my son was stricken with a very rare blood disorder, and we were forced to live in a children’s hospital in Los Angeles for many weeks. I was able to see, first hand, how such a tragedy can financially ruin a family.
The bill for merely the first two weeks in the hospital came to just over $99,000 dollars. One bag of transfusable blood alone cost over $700 dollars. Our son faces a minimum of another 12 to 18 months of treatment. Without insurance, we would have been forced to declare bankruptcy, at the very least. There are thousands of families seeking care for loved ones with life-threatening and chronic afflictions every day. Sadly, the truth is there are many, many families that are turned away from facilities in this great country, only because they do not have enough medical insurance. Please help the gracious people of ZIAD provide care for the underinsured. If you have ever had a loved one need medical attention, you know the urgency of their mission.
Thank you, and may God bless your family with perfect health,
Paul Ganus
Nearly 46 million Americans, including more than 8 million children, are living without health insurance – forced to gamble every day that they won’t get sick or injured. That’s a risk no one should have to take. Uninsured Americans live sick and die younger than those with health insurance. Just one serious illness or injury can wipe out an uninsured family’s bank account, and the problem is getting worse.
To provide health care, health education, physical fitness and other programs to uninsured, under insured, poor, working poor families, and individuals. To provide access to health care in underserved areas, and to the frail elderly.
1) Expand the network of Private doctors offices, and services working with Z.I.A.D. Healthcare for the Underserved that provide primary healthcare as well as other services to underserved, poor, and working poor, and on a sliding scale basis to other geographical areas.
2) Expand services and assistance to the frail elderly.
3) To participate and collaborate with other organizations helping the uninsured or underinsured.
3) To participate and collaborate with Specialty, Pharmacy, Hospital, Dental and other programs to help the uninsured.
4) To identify, apply for and obtain grants that provide screening and outreach to identify disease early up.
Affiliates:
Donations: ZIAD Health Care for the Underserved Inc. is open to all donations public and private and has received Tax Exempt Status with the IRS (#75-3080830).
Donations can be made to ZIAD Health Care via PayPal. Below are buttons that you can use to donate now. We appreciate your donations very much.
Here is a placebo controlled trial explained simply: researchers compare an investigational intervention with an inactive or simulated intervention so they can estimate whether the investigational treatment produces a difference beyond background changes and expectations. The control group provides the reference point. However, “placebo-controlled” does not automatically mean randomized, double-blind, ethical in every situation, or better than a trial using established treatment as the comparator.
The most important question is not whether a study used a placebo. It is whether the control group matched the question being asked. A placebo comparison can show whether a treatment performs better than an inactive control under the study conditions. An active-comparator trial is usually more informative when the practical question is whether a new treatment works as well as or better than existing care.
In a placebo-controlled trial, one group receives the intervention under investigation and another receives a placebo. Researchers then compare the groups’ outcomes. A placebo is designed to resemble the intervention without containing its specific therapeutic component—for example, an inactive tablet made to look like the study medication.
A procedure study may require a sham control rather than a pill. A sham procedure attempts to reproduce relevant parts of the treatment experience without delivering the key therapeutic step. This can help separate the specific effect of a procedure from changes related to attention, expectations, preparation, or recovery routines. Because sham procedures can carry burdens and risks, their scientific value and ethical acceptability require careful review.
Imagine a 12-week trial of an investigational treatment for recurring symptoms. Participants in one group receive the treatment, while participants in another receive a matching placebo. If symptoms improve more in the treatment group, the difference between the groups—not merely improvement within the treatment group—is the central result.
That last distinction matters because people can improve during a study for many reasons. Symptoms may fluctuate, participants may change other behaviors, additional attention may affect reporting, or people may enter a trial when symptoms are unusually severe and later move closer to their typical level.
The placebo group is not simply a group in which “nothing happens.” Participants still experience the passage of time, study visits, assessments, expectations, natural changes in illness, and sometimes background standard care. The control group helps show what outcomes might look like without the investigational treatment’s specific component.
A useful way to read the result is:
This is why a headline saying that 60% of treated participants improved can be incomplete. If 55% of the placebo group also improved, the relevant contrast is much smaller than the treatment-group percentage suggests. The study’s statistical analysis, outcome definition, missing data, and uncertainty around the estimate also matter.
These design features are often discussed together, but each addresses a different potential source of bias.
Random assignment uses a chance-based process to place participants into study groups. Its purpose is to make the groups comparable at the beginning, including with respect to characteristics researchers did not measure. Randomization does not guarantee perfectly identical groups, especially in a small study, but it reduces systematic selection of who receives which intervention.
Allocation concealment means the person enrolling a participant cannot predict the next assignment. If the upcoming assignment were known, conscious or unconscious decisions about enrollment could produce systematically different groups. Concealment therefore protects the randomization process before assignment occurs.
Blinding, also called masking, concerns who knows which intervention a participant received after assignment. Participants, treating clinicians, outcome assessors, data analysts, or some combination of these people may be blinded.
Current CONSORT guidance recommends reporting exactly who was blinded instead of relying only on broad terms such as “single-blind” or “double-blind.” Those labels can mean different things in different reports. A reader should look for a concrete statement such as, “participants and outcome assessors were unaware of treatment assignment.”
Not every intervention can be fully blinded. Participants generally know whether they attended an exercise program, for example. Researchers may still blind outcome assessors or use objective outcomes when appropriate. The key is to identify who could know the assignment and how that knowledge might influence care, behavior, reporting, or measurement.
When a treatment “beats placebo,” the treatment and placebo groups differed according to the study’s prespecified analysis. That can provide evidence that the treatment has an effect beyond the control condition. The strength of that conclusion depends on the trial’s execution, sample size, outcome selection, missing data, blinding, and consistency of results.
Beating placebo does not automatically establish that the treatment:
Statistical significance and clinical importance are also different. A small average difference can be unlikely to result from chance under the statistical model while still being too modest to matter to many patients. Readers should look at the size of the benefit, its uncertainty, the type of outcome measured, and the burden or harms of treatment—not only the p-value.
An active comparator is an intervention expected to have a therapeutic effect, often an established treatment or standard-care approach. Control selection should follow the study objective. The ICH guidance on control groups in clinical trials discusses placebo, active-control, superiority, noninferiority, and equivalence designs as tools for answering different questions.
| Design | Main question | Important limitation |
|---|---|---|
| Placebo-controlled | Does the investigational treatment outperform an inactive or simulated control? | It may not reveal how the treatment compares with established care. |
| Active-control superiority | Is the new treatment better than the comparator? | It may require a larger or more complex trial than a placebo comparison. |
| Noninferiority | Is the new treatment not unacceptably worse than established treatment by a prespecified margin? | The conclusion depends heavily on the margin and whether the trial could detect a real difference. |
| Add-on design | Does adding the investigational treatment to background care improve outcomes? | The result applies to the treatment as an addition, not necessarily as a replacement. |
| Three-arm design | How do the investigational treatment, placebo, and an active comparator perform in the same trial? | More groups can increase cost, complexity, and required enrollment. |
Active-control studies require especially careful interpretation when groups have similar outcomes. Similarity could mean that both treatments work, but it could also occur if the study population, adherence, outcome measurement, or other design choices made differences difficult to detect. The FDA describes this issue in terms of whether a trial has assay sensitivity—the ability to distinguish an effective treatment from a less effective or ineffective one.
Noninferiority is not the same as proving equality. Researchers specify a margin representing how much worse the new treatment could be while still meeting the study’s noninferiority criterion. Such a design may be appropriate when a new option could offer another advantage, such as easier administration or fewer burdens, but the margin and evidence supporting it deserve scrutiny.
Placebo use is not ethical or unethical merely because a placebo is present. The central questions include whether effective care exists, what could happen if that care is withheld or delayed, whether participants continue to receive background treatment, and whether safeguards such as rescue medication are available. International ethical guidance treats control selection as a question involving scientific necessity, risk, and participant protection.
A placebo may be easier to justify when no established effective intervention exists and participants are not exposed to serious or irreversible harm by delaying treatment. It becomes much harder to justify when withholding proven care could cause substantial deterioration, disability, or another serious outcome.
Researchers can sometimes answer a placebo-related question without removing standard care. In an add-on trial, all participants continue appropriate background treatment; one group receives the investigational therapy and the other receives a placebo addition. Protocols may also include close monitoring, withdrawal criteria, and rescue treatment if a participant’s condition worsens. Participants should receive understandable information about assignment, alternatives, foreseeable risks, and their right to leave the study.
A placebo response is the observed change among people assigned to placebo. It can include natural recovery, symptom fluctuation, changes in other care, regression toward a typical level, reporting effects, and effects related to expectations or the treatment setting.
A placebo effect refers more narrowly to change caused by the placebo context itself. Researchers cannot calculate that effect merely by observing that the placebo group improved. Separating it from natural change generally requires another comparison, such as a no-treatment group, although that design introduces its own complications.
A Cochrane review found no general evidence that placebo interventions produce clinically important effects across conditions. It identified possible modest effects for some subjective, continuously measured outcomes, while noting that these effects could not be cleanly separated from bias. This is another reason not to describe every improvement in a placebo group as proof of a powerful placebo effect.
Use this checklist when reading a paper, trial summary, or health headline:
No. “Placebo-controlled” identifies the comparator, while “randomized” identifies how participants are assigned. Many rigorous placebo-controlled trials are randomized, but the terms describe different features. Confirm both in the study methods.
No. A trial can use a placebo without blinding every relevant person. Some studies cannot blind treating clinicians, and a poorly matched placebo may allow participants to guess their assignment. Look for a precise account of who was blinded and whether blinding appeared credible.
A placebo can help keep treatment experiences similar across groups. If one group receives a convincing intervention and the other receives nothing, expectations, attention, and reporting behavior may differ substantially. A matching placebo can reduce those differences, although it cannot control every aspect of the study experience.
Yes. In an add-on design, participants in both groups receive background standard care. They then receive either the investigational treatment or a placebo in addition. This can preserve necessary treatment while testing whether the new intervention adds benefit.
No. It shows superiority to the placebo condition under the trial’s design and analysis. Establishing superiority to existing care generally requires a direct, appropriately designed active-comparator trial. Indirect comparisons between separate trials can be informative, but differences in participants, outcomes, duration, and methods make them less definitive.
A placebo control is a tool, not a universal seal of study quality. It can create a clear reference point for determining whether an intervention has a specific effect, particularly when no established effective treatment must be withheld. But it may answer a narrower question than patients and clinicians ultimately face.
When interpreting a trial, start with three questions: What did the control group receive? Who knew the assignments? What comparison does the result actually support? Those questions quickly reveal whether the study shows an advantage over an inactive control, an advantage over existing care, or only an early signal that requires a more practical comparison.